About BRII-B Company

Tengsheng Pharmaceutical is a leading biotechnology company. Through pipeline prioritization and organizational optimization, it is committed to developing innovative therapeutics in fields where medical needs are highly unmet, especially infectious diseases. Tengsheng Pharmaceuticals has always adhered to its mission of addressing public health challenges through groundbreaking scientific innovation and critical patient insight. The clinical strategy of Tengshengbo Pharmaceutical focuses on determining the most effective treatment plan for different subgroups of HBV patients while seeking the most efficient regulatory approval path. This strategy involves a number of ongoing phase 2 clinical studies, namely the ENSURE study, the ENRICH study, and the ENHANCE study. These studies tested different HBV combination treatment options, including BRII-179 (a recombinant protein-based HBV immunotherapy), elebsiran (a siRNA targeting HBV), and tobevibart (a broadly neutralizing monoclonal antibody targeting HBV surface antigens). These assets all provide a unique therapeutic perspective. Among them, Teng Shengbo Pharmaceutical believes that BRII-179 is a key differentiating factor, and can achieve curative goals by stimulating and restoring HBV-specific immune responses. These studies have systematically confirmed Tengshengbo Pharmaceutical's joint strategy through multiple test methods. In particular, it can validate patient enrichment as a strategy to optimize functional healing outcomes and guide decisions related to registration pathways. Based on recognition of Tengshengbo Pharmaceutical's innovative drug candidates for the treatment of HBV, elebsiran, Tobevibart, and BRII-179 have all been certified as breakthrough therapeutic varieties by the Drug Evaluation Center (CDE). In June 2024, Vir Biotechnology was also granted fast-track certification by the US FDA for the treatment of chronic hepatitis D with Elebsiran and Tobevibart, and then Vir Biotechnology was granted orphan drug qualification by the EMA in November 2024. In December 2024, Vir Biotechnology was granted breakthrough therapy certification by the US FDA and priority drug certification by EMA. While highly focused on its HBV functional cure program, the development of Tengsheng Pharma's other clinical projects (including drug candidates for HIV and MDR/XDR infections) will depend on obtaining external partnerships. In October 2024, Tengshengbo Pharmaceutical's MDR/XDR infection project BRI693 received IND approval from CDE to conduct a Phase 1 PK bridging study in China. With the expansion of the early development team and the appointment of the Chief Scientific Officer in 2024, Tengsheng Pharmaceuticals has also strengthened its early research pipeline in the field of new target and platform technology. This strategic investment reinforces Tengsheng Pharma's commitment to advancing research and providing cutting-edge solutions to patients around the world.